EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial

Jonas Saal, Tobias Bald, Markus Eckstein, Manuel Ritter, Peter Brossart, Jörg Ellinger, Michael Hölzel, Niklas Klümper iD

JNCI Cancer Spectrum · 2023

DOI: 10.1093/jncics/pkad027 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2023. Verfasst von Jonas Saal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Faculty of the University of Bonn.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Static biomarkers like programmed death-ligand 1 (PD-L1) are insufficient to accurately predict response to immune checkpoint inhibition. Therefore, on-treatment biomarkers, which measure immediate therapy-associated changes, are currently shifting into the focus of immuno-oncology. A prime example of a simple predictive on-treatment biomarker is the early C-reactive protein (CRP) kinetics with its predictive CRP flare-response phenomenon. Here, we were able to confirm the predictive value of CRP flare-response kinetics in the pivotal phase III OAK trial (NCT02008227), which compared atezolizumab with docetaxel in patients with non-small cell lung cancer. Of note, CRP flare-response predicted favorable outcomes only in the immune checkpoint inhibition–treated subgroup, which suggests that it is an immunotherapy-specific phenomenon. In conclusion, we have for the first time validated the high predictive value of early CRP kinetics in a pivotal phase III trial, justifying the broad use of this cost-effective and easy-to-implement on-treatment biomarker to optimize therapy monitoring for patients with non-small cell lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansC-Reactive ProteinImmune Checkpoint InhibitorsImmunotherapy

Substanzen

C-Reactive ProteinImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany.
  • Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany.
  • Center for Integrated Oncology, Aachen/Bonn/Collogne/Düsseldorf (CIO-ABCD), Bonn, Germany.
  • Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.

ORCID-Profile: Niklas Klümper

Förderung

  • Medical Faculty of the University of Bonn

Zitieren

APA

Saal, J., Bald, T., Eckstein, M., Ritter, M., Brossart, P., Ellinger, J., Hölzel, M., & Klümper, N. (2023). Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkad027

Vancouver

Saal J, Bald T, Eckstein M, Ritter M, Brossart P, Ellinger J, et al. Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial. JNCI Cancer Spectrum. 2023. doi:10.1093/jncics/pkad027

BibTeX
@article{Saal2023,
  author = {Saal, Jonas and Bald, Tobias and Eckstein, Markus and Ritter, Manuel and Brossart, Peter and Ellinger, Jörg and Hölzel, Michael and Klümper, Niklas},
  title = {Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial},
  journal = {JNCI Cancer Spectrum},
  year = {2023},
  doi = {10.1093/jncics/pkad027}
}
Kostenlos starten →